[go: up one dir, main page]

WO2009004971A1 - 関節リウマチの予防・治療剤 - Google Patents

関節リウマチの予防・治療剤 Download PDF

Info

Publication number
WO2009004971A1
WO2009004971A1 PCT/JP2008/061620 JP2008061620W WO2009004971A1 WO 2009004971 A1 WO2009004971 A1 WO 2009004971A1 JP 2008061620 W JP2008061620 W JP 2008061620W WO 2009004971 A1 WO2009004971 A1 WO 2009004971A1
Authority
WO
WIPO (PCT)
Prior art keywords
articular rheumatism
therapeutic agent
prophylactic
stage
apolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061620
Other languages
English (en)
French (fr)
Inventor
Tetsuya Sasaki
Naoko Hara
Makoto Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Pharmaceutical Co Ltd
Original Assignee
Nihon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Pharmaceutical Co Ltd filed Critical Nihon Pharmaceutical Co Ltd
Publication of WO2009004971A1 publication Critical patent/WO2009004971A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

【課題】本発明の課題は、関節リウマチの初期から進行した状態のいずれの段階においても副作用を生じることなく症状の進行を抑制、緩和することのできる関節リウマチ予防・治療剤を提供することにある。 【解決手段】アポリポタンパク質Ａ－IIは高密度リポタンパク質（ＨＤＬ）の主要な構成タンパク質の一種であるが、そのアポリポタンパク質Ａ－IIを有効成分として含有する非経口投与用医薬組成物が安全且つ効果的に関節リウマチの予防・治療剤として使用することができることが判明した。
PCT/JP2008/061620 2007-06-29 2008-06-26 関節リウマチの予防・治療剤 Ceased WO2009004971A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-171652 2007-06-29
JP2007171652A JP2010208946A (ja) 2007-06-29 2007-06-29 関節リウマチの予防・治療剤

Publications (1)

Publication Number Publication Date
WO2009004971A1 true WO2009004971A1 (ja) 2009-01-08

Family

ID=40226018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061620 Ceased WO2009004971A1 (ja) 2007-06-29 2008-06-26 関節リウマチの予防・治療剤

Country Status (2)

Country Link
JP (1) JP2010208946A (ja)
WO (1) WO2009004971A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020009424A1 (ko) * 2018-07-03 2020-01-09 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도
KR102276941B1 (ko) 2018-07-03 2021-07-14 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032328A2 (en) * 2003-05-21 2005-04-14 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005086578A2 (en) * 2004-03-08 2005-09-22 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-inflammatory peptides and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032328A2 (en) * 2003-05-21 2005-04-14 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005086578A2 (en) * 2004-03-08 2005-09-22 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-inflammatory peptides and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] DAYER J.M.: "The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis", Database accession no. (12027302) *
JOINT BONE SPINE, vol. 69, no. 2, 2002, pages 123 - 132 *
VAN DEN BERG W.B.: "Anti-cytokine therapy in chronic destructive arthritis", ARTHRITIS RES., vol. 3, no. 1, 2001, pages 18 - 26, XP001149544 *
YAMADA T. ET AL.: "Decreased serum apolipoprotein AII/AI ratio in systemic amyloidosis", ANN. RHEUM. DIS., vol. 57, no. 4, 1998, pages 249 - 251 *

Also Published As

Publication number Publication date
JP2010208946A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
EP4149460B8 (en) Therapeutic solid dosage forms
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL197574A0 (en) Pharmaceutical compositions
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008071573A3 (en) Powder formulation for valganciclovir
WO2010109482A3 (en) Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
IL287103A (en) Improved performance of amorphous solids and factor formulations to achieve therapeutic plasma concentrations
WO2009081174A3 (en) Anti - retroviral combination
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
HK1217092A1 (zh) 治疗性化合物及其用途
WO2007092469A3 (en) Combination of organic compounds
WO2013106068A3 (en) Therapeutic compositions of specified herbal formulations and uses thereof
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2011072069A3 (en) Gastric retentive pharmaceutical compositions for extended release of polypeptides
WO2006044805A3 (en) Less abusable pharmaceutical preparations
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2012064302A3 (en) Improved montelukast formulations
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
WO2009004971A1 (ja) 関節リウマチの予防・治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790635

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08790635

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP